Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design
Adrenal Cortex Hormones
Adrenergic beta-2 Receptor Agonists
Budesonide, Formoterol Fumarate Drug Combination
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Phosphodiesterase 4 Inhibitors
Pulmonary Disease, Chronic Obstructive
This study will further characterize the effects of roflumilast added to ICS/LABA on exacerbation rates, lung function, and health of severe-very severe COPD participants at risk of further exacerbations. The results will determine the clinical benefits of roflumilast combined with standard-of-care inhaled COPD treatment.